Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
-7.87% $8.08
America/New_York / 24 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 544.40 mill |
EPS: | -1.960 |
P/E: | -4.12 |
Earnings Date: | May 06, 2024 |
SharesOutstanding: | 67.38 mill |
Avg Daily Volume: | 0.570 mill |
RATING 2024-04-24 |
---|
B- |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Neutral | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Sell | |
Price To Book: | Neutral |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -4.12 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.70x |
Company: PE -4.12 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$0.256 (-96.83%) $-7.82 |
Date: 2024-04-25 |
Expected Trading Range (DAY) |
---|
$ 7.17 - 8.99 ( +/- 11.30%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Chacko Jacob | Sell | 40 000 | Common Stock |
2024-02-06 | Chacko Jacob | Sell | 13 958 | Common Stock |
2024-02-07 | Chacko Jacob | Sell | 26 042 | Common Stock |
2024-01-02 | Multani Pratik S | Buy | 180 000 | Stock Option (right to buy) |
2024-01-02 | Multani Pratik S | Buy | 30 000 | Restricted Stock Unit |
INSIDER POWER |
---|
54.24 |
Last 99 transactions |
Buy: 6 373 472 | Sell: 3 807 004 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $8.08 (-7.87% ) |
Volume | 0.368 mill |
Avg. Vol. | 0.570 mill |
% of Avg. Vol | 64.55 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $12.30 | N/A | Active |
---|
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.